Development and evaluation of aceclofenac-loaded mucoadhesive microcapsules

Santhosh Kumar Mankala1, Appanna Chowdary Korla, Sammaiah Gade

  • 1Department of Pharmaceutics, Vaageswari College of Pharmacy, Beside LMD Police Station, Ramakrishna Colony, Karimnagar, Andhra Pradesh, India.

Insights

This study developed sustained-release aceclofenac microcapsules using sodium alginate and mucoadhesive polymers. The best formulation, containing hydroxypropyl methyl cellulose (HPMC), demonstrated prolonged drug release and mucoadhesion for improved therapeutic effects.

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems
  • Materials Science

Background:

  • Microencapsulation is vital for controlled drug release and targeting.
  • Mucoadhesion enhances drug bioavailability by prolonging intestinal residence time.
  • Aceclofenac, a nonsteroidal anti-inflammatory drug (NSAID), requires sustained release due to its short half-life.

Purpose of the Study:

  • To prepare and evaluate aceclofenac microcapsules for sustained release and mucoadhesion.
  • To investigate the impact of mucoadhesive polymers on microcapsule properties and drug release kinetics.
  • To identify the optimal formulation for prolonged aceclofenac delivery.

Main Methods:

  • Aceclofenac microcapsules were prepared using the orifice-ionic gelation technique with sodium alginate and mucoadhesive polymers (HPMC, Sod. CMC, Carbopol, MC).
  • Formulation compatibility was confirmed using Infrared (IR) spectroscopy, differential scanning calorimetry, and X-ray diffraction.
  • Microcapsules were characterized for size, morphology (SEM), flow properties, encapsulation efficiency, swelling index, mucoadhesion (in vitro wash-off test), and in vitro drug release (up to 24 hours).

Main Results:

  • Microcapsules were spherical, discrete, and free-flowing, with sizes ranging from 757.44 to 814.46 μm.
  • Hydroxypropyl methyl cellulose (HPMC) formulations showed higher encapsulation efficiency and good mucoadhesion.
  • The drug:SA:HPMC (2:4:1) formulation exhibited the most sustained drug release over 24 hours, following zero-order kinetics with Super Case II mechanism.

Conclusions:

  • Aceclofenac microcapsules prepared with sodium alginate and HPMC are effective for sustained drug delivery.
  • The optimized formulation demonstrates significant mucoadhesive properties and prolonged drug release, indicating potential for improved therapeutic outcomes.
  • The orifice-ionic gelation technique is suitable for developing mucoadhesive microcapsules for NSAID delivery.

Related Concept Videos

Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.